About

About BioPorto Diagnostics Acute Kidney Injury (AKI) adversely impacts 25% of critically ill children and can be hard to identify with serum creatinine alone. ProNephro AKI™ (NGAL) is the first FDA-cleared test for assessing AKI risk in ICU patients aged 3 months to 22 years. A low NGAL result indicates a low risk of AKI, allowing for confident use of interventions such as fluids, diuretics, or nephrotoxic medications. Elevated NGAL values signal a high risk of developing AKI, triggering nephrology consults and interventions 2-3 days before serum creatinine rises.Visit booth 1342 to learn how ProNephro AKI (NGAL) can improve AKI management in your patients and get an update on our adult clinical trial. https://bioporto.us/pronephro-aki/